We compared the clinical course of neonates with persistence of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) in the cerebrospinal fluid (CSF) after 21 days of treatment with high-dose acyclovir to that of neonates with clearance of the CSF after 21 days of therapy. Neonates with persistence of HSV DNA had a more severe clinical course with worse neurodevelopmental outcomes.
Herpes simplex virus (HSV) infection occurs in ~1500 neonates each year in the United States, presenting on a continuum from skin, eye, and mouth (SEM) disease (~45% of cases) to disseminated disease (~25%) to central nervous system (CNS) infection (~30%) [1, 2] . Significant morbidity and mortality is associated with CNS infections [3] . Polymerase chain reaction (PCR) testing has been well described as a diagnostic tool to detect the presence of HSV in the cerebrospinal fluid (CSF) and is commonly used to diagnose HSV disease with CNS involvement [4, 5] .
Practice guidelines recommend that neonates with CNS involvement receive 21 days of high-dose intravenous acyclovir (60 mg/kg per day), because patients treated with that regimen had decreased mortality and improved outcomes [2, 6] . Persistence of HSV deoxyribonucleic acid (DNA) in the CSF (pHSV) after treatment rarely has been reported and has been associated with increased morbidity and mortality, but its full clinical significance is unknown [4, 7, 8] . Previous reports of pHSV did not compare outcomes to those with clearance or were performed before treatment with high-dose acyclovir was standard. We report the first comparison of clinical course and outcomes for neonates with pHSV and those with clearance of HSV DNA from the CSF after standard treatment with highdose acyclovir.
METHODS
In this retrospective analysis from 2003-2014, patients were identified from an Infectious Diseases consult list of suspected neonatal HSV infection maintained at a Midwest tertiary pediatric hospital. Ninety patients were on this list, and the medical record was reviewed to identify neonates with confirmed HSV CNS disease, defined by positive CSF PCR testing before the onset of therapy.
Data relating to basic demographics (including maternal characteristics), presentation, and clinical course were collected. The results of neuroimaging, microbiological testing, and laboratory studies were trended throughout hospitalization. Cerebrospinal fluid indices were collected from lumbar punctures at admission and within 48 hours of completion of 21 days of high-dose acyclovir. All patients included in this study underwent lumbar puncture at the completion of 21 days of acyclovir therapy.
As standard of care, patients had continued follow-up in the Infectious Diseases and Neurology clinics, with detailed neurological examination performed at each visit. Data related to use of suppressive acyclovir, recurrences of infection, and neurodevelopmental outcomes were collected from follow-up visits for 2 years after discharge. Retrospective assessment of neurodevelopmental outcome and overall function was performed at each follow-up visit. Patients were classified based upon level of impairment (normal, impaired but living at home, or institutionalized). They were defined as having mild impairment if they had ocular sequelae such as recurrent keratoconjunctivitis, speech delay, or mild motor delay without hemiparesis; moderate impairment if hemiparesis, refractory seizures, or developmental delay of <3 months were present; and severe impairment if microcephaly, spastic quadriplegia, blindness, or developmental delay of >3 months were noted [6, 9, 10] .
Patients with pHSV, defined as those with positive HSV PCR testing at the end of 21 days of high-dose acyclovir therapy, were then compared with those with clearance of HSV from the CSF after 21 days of therapy. Statistical analysis was performed using Microsoft Excel (2011), Student's t test was used for continuous variables, and Fisher's was used exact test for categorical variables. Significance was set at P < .05.
RESULTS
Of the 90 charts reviewed, 46 neonates had HSV infection. Twenty patients had SEM disease, 9 had CNS disease, and 17 had disseminated disease (12 with CNS involvement). Of those with CNS involvement, 3 patients were excluded: one due to age >3 months, a second due to death before completion of therapy, and a third because the presentation at our institution represented recurrent disease. Four patients were diagnosed with pHSV, and 14 patients had clearance of HSV DNA from the CSF at the end of 21 days of acyclovir therapy. All patients with pHSV were males, and all were infected with HSV-II.
Results of the comparison between patients with pHSV and those with clearance of HSV from the CSF are shown in Table 1 . There was no significant difference in maternal or birth characteristics or method of delivery. There were no significant differences between cohorts with respect to baseline clinical characteristics and laboratory results at admission. There was no significant difference in CSF studies obtained at admission in those with pHSV compared with those with HSV clearance at 21 days (white blood cells, 59 ± 36 vs 209 ± 104; red blood cells, 11878 ± 6874 vs 13674 ± 12515; protein 130 ± 32 vs 103 ± 13; glucose, 39 ± 20 vs 45 ± 3). No patient in either cohort had delayed initiation of acyclovir, defined as initiation of acyclovir therapy >1 day after admission [11] .
Patients with disseminated HSV that were found to have pHSV had significantly elevated total bilirubin during the first week of therapy (6.0 ± 0.5 vs 2.0 ± 0.3 mg/dL, P < .0001). Patients with pHSV had a more severe disease course, with continued seizure activity during the third week of acyclovir therapy despite antiepileptic therapy (P = .039). Patients with pHSV had elevated protein in CSF obtained at the completion of 21 days of acyclovir therapy (277 ± 50 vs 89 ± 14 mg/dL, P < .001). Other CSF indices were similar between groups (red blood cells, 1566 ± 1151 vs 887 ± 587; white blood cells, 53 ± 15 vs 71 ± 53; glucose, 37 ± 4 vs 37 ± 1).
All patients with pHSV received prolonged acyclovir therapy after diagnosis; 3 patients received treatment for 28 days, and 1 patient received treatment for 35 days. Clearance of CSF was confirmed for 3 patients with pHSV before stopping therapy; the last patient received 28 days of acyclovir but did not undergo a third lumbar puncture to confirm clearance of HSV DNA from the CSF. A majority of patients received suppressive therapy with acyclovir after discharge, and there was no difference in the rate of relapse between cohorts. Patients with pHSV had a significant increase in the incidence of cortical blindness (P = .039) and other visual sequelae. There was no significant difference in the frequency or quality of the seizure disorders between those with persistence and those without. The most severe seizure disorder (daily seizures despite antiepileptic medications) did occur in a patient with pHSV. However, another patient with pHSV was well controlled with antiepileptic medications. Patients with clearance of HSV DNA rarely had seizures once antiepileptic therapy was initiated. There were no statistically significant differences in developmental outcomes, but there was a trend toward moderate-to-severe impairment in patients with pHSV.
DISCUSSION
This is the first reported comparison of the clinical course and outcomes between patients with persistence of HSV DNA in the CSF after 21 days of high-dose acyclovir and those with clearance of the CSF. Kimberlin et al [4] previously reported a comparison between neonates with pHSV and those with clearance of the CSF after treatment with 10 days of vidarabine or low-dose acyclovir. A majority of patients with pHSV in that study had isolated CNS disease, but other clinical characteristics were similar to those seen in our cohort. Those with pHSV had significantly increased morbidity and mortality 12 months after treatment was completed. Mejías et al [8] reported poor neurodevelopmental outcomes in a case series of 4 patients with pHSV after 15-21 days of high-dose acyclovir but did not compare outcomes to those with clearance of HSV. We identified neonates with disseminated and isolated CNS disease who had pHSV and a more severe disease course. All were male and all were infected with HSV-II. Neonates with pHSV had persistent, refractory seizure activity despite treatment with acyclovir. Neurodevelopmental outcomes were worse, with a significantly increased rate of cortical blindness and a trend toward functional impairment.
Infection with HSV-II has been linked with worse neurodevelopmental outcomes [6, 12] . Most notably, all patients with severe neurodevelopmental outcomes in this study (both those with pHSV and those with clearance of HSV) were infected with HSV-II. When the comparison was repeated with only infants infected with HSV-II, there was no statistically significant differences between groups except for increased CSF protein at the end of therapy. It is possible that pHSV is more likely with HSV-II infection, perhaps because HSV-II is relatively less susceptible to acyclovir compared with HSV-I. Further research is needed to determine whether pHSV is characteristic of HSV-II disease and whether there are any differences between those with pHSV and those with clearance of HSV from the CSF after standard treatment amongst those infected with HSV-II.
Other reasons for the development of pHSV have been postulated [8] . Elevated viral load in the CSF at presentation may predispose to the development of pHSV. Elevated viral load has been hypothesized to be a surrogate marker for continued invasion and proliferation by HSV, and pediatric patients with high viral load have been shown to have increased mortality [12] . A viral load from the CSF at presentation was not obtained in any patient in our study. Resistance to antiviral therapy has also been reported in neonates with poor response to acyclovir therapy [8] . Complete antiviral resistance or even relative susceptibility to antivirals (with increased half maximal inhibitory concentrations) could theoretically impact the occurrence of pHSV, as could low concentrations of acyclovir in the blood or CSF due to rapid drug metabolism. However, the fact that the 3 subjects with documented eventual clearance of HSV DNA from their CSF did so while only receiving acyclovir (and not the addition of foscarnet, for example) suggests that these were not factors in pHSV in this small case series. Individual genetic susceptibility to HSV infection may also play a role in persistence of HSV infection.
CONCLUSIONS
This is the first study to describe the clinical course in pHSV in neonates compared with those without persistence of HSV DNA in the CSF, demonstrating the association of pHSV with worse outcomes. Future investigations should be performed with larger sample sizes to better define pHSV and to evaluate whether neonates with pHSV have a genetic susceptibility to HSV infection, whether initial viral loads are greater, or whether acyclovir resistance plays a role. Such information will help inform as to the need and efficacy of prolonging therapy with acyclovir.
